HEALWELL AI Inc. announced the signing of services agreements with each of WELL Health USA (?WELL USA?) and its affiliate Circle Medical Technologies Inc. (?Circle Medical?), a subsidiary of WELL Health Technologies Corp., bringing artificial intelligence (?AI?) powered preventative care solutions to U.S. patients. Under the terms of the services agreements, HEALWELL will provide U.S. patients with access to its subsidiaries Pentavere Research Group Inc. (?Pentavere?) and Khure Health Corporation (?Khure?) for the purposes of earlier diagnosis and identification of patients with potential risk of certain conditions, identification of patient eligibility for approved medications or interventions, optimizing patient care pathways and improving patient health outcomes. WELL USA?s CRH Medical which has over 100 Gastrointestinal (GI) only sites of service, has identified data from approximately 200,000 patients across 21 states that can be analyzed, in a secure and compliant manner using Pentavere?s DARWEN?

AI platform. The platform can enable high-quality, real-world data generation on the relationships between biologic prescribing, clinic-demographics, and outcomes to support patients suffering from Inflammatory bowel disease (IBD) and other gastrointestinal conditions. This information is expected to be used to enhance the understanding of how different factors, such as the type of medication prescribed and patient characteristics, relate to treatment outcomes.

The partnership will ultimately help support sub-optimally treated IBD disease patients in the US, reducing healthcare costs and the burden on healthcare systems. HEALWELL?s Khure has also partnered with U.S. based Circle Medical, a subsidiary of WELL Health, to integrate its proprietary AI platform with Circle?s electronic medical record (EMR) system, expanding its footprint into the US. Circle Medical currently provides virtual care services in over 30 states and has 23 physical locations across the US, representing access to over 75% of the American population. Khure will be able to analyze Circle?s large U.S. clinical data-sets, using its proprietary machine learning algorithms to screen for and flag individual patients whom the health care practitioner might want to consider for further investigation for certain conditions and identifying those patients for early diagnosis of rare disease.

Khure will also have the ability to screen for U.S. patient cohorts that may be candidates for clinical trial eligibility. Circle Medical is a leader in providing primary based care in the US and it is currently on a run-rate of delivering more than 700,000 patient visits per year and growing quickly.